Primary bone cancer is one of the rarest cancers. It accounts for just 0.2% of all new cancer diagnoses in the United States, with an estimated 4,110 new cases expected in 2026. To put that in perspective, breast cancer produces roughly 300,000 new cases per year, and lung cancer about 230,000. Bone cancer barely registers by comparison.
How Rare Qualifies as “Rare”
The CDC defines a rare cancer as one with fewer than 15 cases per 100,000 people per year. Primary bone cancer falls well below that line, with an incidence rate of roughly 1 case per 100,000 people annually. That makes it rare even among rare cancers. Your lifetime probability of developing primary bone cancer is very low, roughly 1 in 1,000 or less depending on age and sex.
Primary Bone Cancer vs. Cancer That Spreads to Bone
This is a critical distinction most people miss. Primary bone cancer, where the cancer actually starts in bone cells, is genuinely rare. But cancer that spreads to the bones from somewhere else (called metastatic or secondary bone cancer) is far more common. Breast, prostate, lung, kidney, and thyroid cancers all frequently metastasize to bone. When doctors find cancer in a bone, it’s much more likely to be a secondary cancer that traveled there than a true bone cancer.
The two situations are treated very differently. Metastatic bone cancer is still classified and treated as the original cancer type, because the cells themselves haven’t changed. A breast cancer that has spread to the spine is still breast cancer, not bone cancer.
The Three Main Types
Primary bone cancer isn’t a single disease. The three most common subtypes each tend to strike different age groups.
- Osteosarcoma is the most common type overall. It typically appears in teenagers and young adults during periods of rapid bone growth, often in the long bones of the legs or arms. It can also occur in adults over 60, sometimes linked to other bone conditions.
- Chondrosarcoma starts in cartilage cells and is more common in adults over 40. It tends to grow more slowly than osteosarcoma and most often develops in the pelvis, upper leg, or shoulder.
- Ewing sarcoma is the rarest of the three and primarily affects children and teenagers. It can appear in bones or in the soft tissue around them, and it most commonly involves the pelvis, chest wall, or legs.
Each of these subtypes individually is extremely uncommon. Ewing sarcoma, for instance, is diagnosed in only about 200 children and young adults per year in the U.S.
Who Gets It
Unlike most cancers, which become more common with age, primary bone cancer has an unusual age pattern. There’s a peak in adolescence and early adulthood (particularly for osteosarcoma and Ewing sarcoma), a quiet period through middle age, and then a smaller rise again after age 60 (largely driven by chondrosarcoma). Males are slightly more likely to be diagnosed than females.
Most people who develop primary bone cancer have no known risk factors. A small number of cases are linked to inherited genetic conditions like Li-Fraumeni syndrome or hereditary retinoblastoma. Prior radiation therapy to a bone area can also increase risk, though this remains uncommon. Paget’s disease of bone, a condition that causes abnormal bone remodeling in older adults, is associated with a slightly elevated risk of osteosarcoma.
Survival Rates by Stage
Because bone cancer is rare, survival statistics come from relatively small patient groups, but the general pattern is clear: catching it early matters enormously. When primary bone cancer is still localized (confined to the bone where it started), the five-year relative survival rate is roughly 75 to 80%. Once it has spread to nearby tissues or lymph nodes, that drops to around 65%. If it has metastasized to distant parts of the body, typically the lungs, survival falls to approximately 25 to 30%.
These numbers vary significantly by cancer type. Chondrosarcoma, which grows slowly, generally carries a better prognosis than Ewing sarcoma or high-grade osteosarcoma. Age at diagnosis, tumor location, and how well the cancer responds to initial treatment all influence individual outcomes.
Why Rarity Creates Challenges
Being rare creates practical problems. Symptoms of bone cancer, particularly persistent bone pain, swelling near a joint, or an unexplained fracture, overlap with far more common conditions like sports injuries, growing pains, or arthritis. Because doctors reasonably consider common explanations first, bone cancer can take longer to diagnose. In teenagers especially, months of “growing pains” sometimes turn out to be something more serious.
Rarity also means fewer specialists, fewer clinical trials, and less pharmaceutical investment compared to common cancers. Patients often need to travel to major cancer centers for treatment. The upside is that these specialized centers have concentrated expertise precisely because they see a higher volume of these unusual cases.